Medtronic, a healthcare technology company based in Ireland, plans to separate its diabetes business into a standalone, publicly traded company by the end of 2026.  The company announced the move May ...

His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech ...

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

Medtronic (NYSE: MDT) announced today that it received CE mark for several expanded indications for its Prevail balloon ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes ...

Integration of Abbott's glucose-ketone sensor with the twiist™ AID System aims to enhance early identification of rising ketones to detect the risk of diabetic ketoacidosis (DKA)1 MANCHESTER, N.H., ...

Medtronic anticipates the separation of its diabetes business unit into a wholly separate entity to complete within 18 months ...

Medtronic (NYSE:MDT) reported better-than-expected fiscal Q4 earnings and revenue, while unveiling plans to spin off its ...

Global medical device company Medtronic announced Wednesday that it intends to separate its diabetes business into a ...

The medical device giant, which is domiciled in Dublin, Ireland but has its main office in Fridley, Minnesota, confirmed that ...

Medtronic has unveiled plans to spin off its diabetes unit into its own publicly traded company that would be headquartered ...

The company says it plans to separate the two entities within 18 months but will still need to get the approval of the ...